CD274 and neoplasm: Immune checkpoint inhibitors such as nivolumab and pembrolizumab could reverse T cell dysfunction and apoptosis by inhibiting the effects of the interaction of programmed death-1 (PD-1) and its ligand PD-L1 to enhance T cell activation and cytotoxicity to tumour cells [184,185].